INTERNATIONAL SECOND OPINION

Part II: Case-Based Discussions Focused on the Management of Multiple Myeloma

TARGET AUDIENCE
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of multiple myeloma (MM).

OVERVIEW OF ACTIVITY
Taken together, it is estimated that approximately 148,040 new lymphoid and myeloid cancer cases were identified in the United States in the year 2012, and 54,380 individuals died from these diseases. Of importance, currently more than 50 drug products are labeled for use in the management of hematologic cancers, with more than 60 distinct FDA-approved indications. Although this extensive list of available treatment options is reassuring for patients and oncology healthcare professionals, it poses a challenge to the practicing clinician who must maintain up-to-date knowledge of appropriate clinical management strategies across a vast spectrum of liquid and solid tumors. These proceedings from a CME symposium during the 54th ASH Annual Meeting use the perspectives of renowned experts in the field of hematologic oncology on cases provided by an international panel of community oncologists from the United States, India, Italy and Spain to frame a relevant discussion of the optimal management of MM. By providing information on the latest research developments and their potential application to routine practice, this activity is designed to assist hematologists, medical oncologists and hematology-oncology fellows with the formulation of up-to-date clinical management strategies for MM.

LEARNING OBJECTIVES
• Appraise recent data on therapeutic advances and changing practice standards in MM, and integrate this information, as appropriate, into current clinical care.
• Use prognostic and predictive clinical and molecular markers to aid in treatment decision-making for MM.
• Compare and contrast the benefits and risks of immunomodulatory agents, proteasome inhibitors or both as systemic treatment for active MM.
• Identify patients with MM who may benefit from maintenance systemic treatment in both the post-transplant and nontransplant settings.
• Recall new data with investigational agents demonstrating promising activity in MM.
• Assess ongoing clinical trials evaluating innovative investigational approaches for MM, and obtain consent from appropriate patients for study participation.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Research To Practice designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY
This CME activity consists of a video component. To receive credit, the participant should watch the video, complete the Post-test with a score of 70% or better and fill out the Educational Assessment and Credit Form located on our website at ResearchToPractice.com/ASHMM13/Video/CME.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the
RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

**FACULTY** — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

**Sergio Giralt, MD**  
Chief, Adult Bone Marrow Transplant Service  
Memorial Sloan-Kettering Cancer Center  
New York, New York

**Advisory Committee and Speakers Bureau:** Celgene Corporation, Genzyme Corporation, Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals Inc; **Educational Material Prep:** Novartis Pharmaceuticals Corporation.

**A Keith Stewart, MBChB**  
Dean for Research, Mayo Clinic in Arizona  
Consultant, Division of Hematology/Oncology  
Vasek and Anna Maria Polak Professorship in Cancer Research  
Scottsdale, Arizona

**Advisory Committee:** Amgen Inc, Celgene Corporation; **Consulting Agreements:** Celgene Corporation, Millennium: The Takeda Oncology Company; **Contracted Research:** Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals Inc.

**Ravi Vij, MD**  
Associate Professor of Medicine  
Washington University School of Medicine  
Section of Stem Cell Transplant and Leukemia  
Division of Medical Oncology  
St Louis, Missouri

**Consulting Agreements:** Abbott Laboratories, Bristol-Myers Squibb Company, Celgene Corporation, Onyx Pharmaceuticals Inc; **Contracted Research:** Celgene Corporation, Onyx Pharmaceuticals Inc; **Speakers Bureau:** Celgene Corporation, Cephalon Inc, Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals Inc.

**Donna E Reece, MD**  
Professor of Medicine  
Director, Program for Multiple Myeloma and Related Diseases  
Princess Margaret Hospital  
Toronto, Ontario

**Advisory Committee:** Celgene Corporation; **Consulting Agreements:** Celgene Corporation, Janssen Pharmaceuticals Inc; **Paid Research:** Bristol-Myers Squibb Company, Celgene Corporation, Janssen Pharmaceuticals Inc, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation.

**Meletios A Dimopoulos, MD**  
Chairman, Department of Medical Therapeutics  
University of Athens School of Medicine  
Athens, Greece

**Advisory Committee:** Celgene Corporation, Novartis Pharmaceuticals Corporation; **Consulting Agreements:** Celgene Corporation, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc.

**CONSULTING ONCOLOGISTS** — The following consulting oncologists (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

**Warren S Brenner, MBChB**  
Center for Hematology/Oncology  
Lynn Cancer Institute  
Boca Raton, Florida

**Speakers Bureau:** Celgene Corporation, Millennium: The Takeda Oncology Company; **Stock Ownership:** Celgene Corporation

**Ramón García-Sanz, MD, PhD**  
Department of Hematology  
Hospital Universitario de Salamanca  
Salamanca, Spain

No real or apparent conflicts of interest to disclose.

**Alberto Grossi, MD**  
Unit of Hematology  
Istituto Fiorentino di Cura e Assistenza (IFCA)  
Florence, Italy

No real or apparent conflicts of interest to disclose.

**Vineet Gupta, MD**  
Principal Consultant, Medical Oncology  
Max Super Speciality Hospital  
Delhi, India

No real or apparent conflicts of interest to disclose.

**Elizabeth D Simmons, MD**  
Physician Lead of Service, Hematology/Medical Oncology  
Kaiser Permanente  
Bellflower, California

Volunteer Faculty  
Harbor-UCLA Medical Center, Hematology  
Torrance, California

No real or apparent conflicts of interest to disclose.

**MODERATOR** — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Algeta US, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly USA LLC, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals,
Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Oncology.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Celgene Corporation, Genentech BioOncology/Biogen Idec, Gilead Sciences Inc, Millennium: The Takeda Oncology Company, Mundipharma International Limited and Teva Oncology.

Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Last review date: March 2013
Expiration date: March 2014
Select Publications

**Sergio Giralt, MD**


Cavo M et al. Superior complete response rate and progression-free survival after autologous transplantation with up-front Velcade-thalidomide-dexamethasone compared with thalidomide-dexamethasone in newly diagnosed multiple myeloma. *Proc ASH* 2008;Abstract 158.


Palumbo A et al. A prospective, randomized study of melphalan, prednisone, lenalidomide (MPR) versus melphalan (200 mg/m²) and autologous transplantation (Mel200) in newly diagnosed myeloma patients: An interim analysis. *Proc ASH* 2009;Abstract 350.


**A Keith Stewart, MBChB**


**Ravi Vij, MD**


Niesvizky R et al. Efficacy and safety of three bortezomib-based combinations in elderly, newly diagnosed multiple myeloma patients: Results from all randomized patients in the community-based, phase 3b UPFRONT study. *Proc ASH* 2011;Abstract 478.


**Donna E Reece, MD**


Richardson PG et al. Phase II study of the pan-deacetylase inhibitor panobinostat in combination with bortezomib and dexamethasone in relapsed and bortezomib-refractory multiple myeloma (PANORAMA 2). *Proc ASH* 2011;Abstract 814.


Vij R et al. Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Outcomes in pts refractory to lenalidomide (LEN) and/or bortezomib (BORT). *Proc ASCO* 2012;Abstract 8016.


**Meletios A Dimopoulos, MD**


